GoAI
Get started
Evolus, Inc. logo

Evolus, Inc.

EOLS

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$8.39

+$0.04 · +0.48%

Aug 21, 4:00 PM ET

EOLS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

91

Deep Value

Momentum

53

Neutral

Sentiment

44

Mixed

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
David Moatazedi
Listed since
Feb 8, 2018
Employees
353

Market position

Day range

Current $8.39

52-week range

Current $8.39

Open
$8.40
Previous close
$8.35
Volume
582.72K
0.67× average
Average volume
867.05K
Average daily volume
Market cap
552.52M USD
Beta
1.36
Market reference 1
50-day average
$6.8181
+23.05% above average
200-day average
$5.9554
+40.88% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
529.89M USD
EV / EBITDA
-23.52×
Earnings yield
-12.05%
Free cash flow yield
-11.83%

Profitability & efficiency

Return on equity
223.50%
Return on assets
-22.86%
Return on invested capital
-24.56%

Financial health

Current ratio
1.9×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends81%34%-14%-62%Gross margin, FY2021: 56.32%Gross margin, FY2022: 60.41%Gross margin, FY2023: 69.54%Gross margin, FY2024: 68.46%Gross margin, FY2025: 64.86%Operating margin, FY2021: -44.55%Operating margin, FY2022: -43.96%Operating margin, FY2023: -24.36%Operating margin, FY2024: -12.92%Operating margin, FY2025: -12.65%Net margin, FY2021: -46.96%Net margin, FY2022: -50.07%Net margin, FY2023: -30.52%Net margin, FY2024: -18.94%Net margin, FY2025: -17.38%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 56.32%. Gross margin FY2022 60.41%. Gross margin FY2023 69.54%. Gross margin FY2024 68.46%. Gross margin FY2025 64.86%. Operating margin FY2021 -44.55%. Operating margin FY2022 -43.96%. Operating margin FY2023 -24.36%. Operating margin FY2024 -12.92%. Operating margin FY2025 -12.65%. Net margin FY2021 -46.96%. Net margin FY2022 -50.07%. Net margin FY2023 -30.52%. Net margin FY2024 -18.94%. Net margin FY2025 -17.38%.

Income trends

Revenue

297.18M USD+11.61%

Operating income

−37.6M USD-9.27%

Net income

−51.64M USD-2.42%
Income trends across reported periods334.33M USD185.7M USD37.06M USD−111.57M USDRevenue, FY2021: 99.67M USDRevenue, FY2022: 148.62M USDRevenue, FY2023: 202.09M USDRevenue, FY2024: 266.27M USDRevenue, FY2025: 297.18M USDOperating income, FY2021: −44.41M USDOperating income, FY2022: −65.33M USDOperating income, FY2023: −49.23M USDOperating income, FY2024: −34.41M USDOperating income, FY2025: −37.6M USDNet income, FY2021: −46.81M USDNet income, FY2022: −74.41M USDNet income, FY2023: −61.69M USDNet income, FY2024: −50.42M USDNet income, FY2025: −51.64M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 99.67M USD. Revenue FY2022 148.62M USD. Revenue FY2023 202.09M USD. Revenue FY2024 266.27M USD. Revenue FY2025 297.18M USD. Operating income FY2021 −44.41M USD. Operating income FY2022 −65.33M USD. Operating income FY2023 −49.23M USD. Operating income FY2024 −34.41M USD. Operating income FY2025 −37.6M USD. Net income FY2021 −46.81M USD. Net income FY2022 −74.41M USD. Net income FY2023 −61.69M USD. Net income FY2024 −50.42M USD. Net income FY2025 −51.64M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue297.18M USD266.27M USD202.09M USD148.62M USD99.67M USD
Cost of goods sold104.41M USD83.97M USD61.56M USD58.84M USD43.53M USD
Gross profit192.76M USD182.3M USD140.53M USD89.77M USD56.14M USD
Research and development9.58M USD9.17M USD15.43M USD6.74M USD2.06M USD
Selling, general, and administrative220.79M USD198.03M USD164.94M USD141.84M USD112.07M USD
Operating expenses230.36M USD216.72M USD189.76M USD155.1M USD100.54M USD
Interest income1.93M USD3.26M USD860K USD119K USD1K USD
Interest expense19.69M USD18.74M USD13.83M USD9.1M USD1.4M USD
Depreciation and amortization8.74M USD6.02M USD5.87M USD3.72M USD6.31M USD
Operating income−37.6M USD−34.41M USD−49.23M USD−65.33M USD−44.41M USD
Net income−51.64M USD−50.42M USD−61.69M USD−74.41M USD−46.81M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-40.35%
11 comparable reports
Latest EPS result
0.01
Estimate -0.03 · Beat by 122.29%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.1-0.03-0.15-0.28Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 0.01, estimate 0.02, surprise -50.00%, Miss. Q2 2025, reported May 7, 2025: actual -0.18, estimate -0.1, surprise -80.00%, Miss. Q3 2025, reported Aug 5, 2025: actual -0.24, estimate -0.09, surprise -166.67%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.14, estimate -0.19, surprise +26.32%, Beat. Q1 2026, reported Mar 3, 2026: actual 0.044, estimate 0.06, surprise -26.30%, Miss. Q2 2026, reported May 4, 2026: actual -0.1, estimate -0.14, surprise +28.57%, Beat. Q3 2026, reported Aug 5, 2026: actual 0.007, estimate -0.033, surprise +122.29%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates93.91M84.1M74.28M64.46MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 78.95M USD, estimate 79M USD, surprise -0.07%, Miss. Q2 2025, reported May 7, 2025: actual 68.07M USD, estimate 82.33M USD, surprise -17.31%, Miss. Q3 2025, reported Aug 5, 2025: actual 69.39M USD, estimate 85.31M USD, surprise -18.67%, Miss. Q4 2025, reported Nov 5, 2025: actual 68.97M USD, estimate 89.61M USD, surprise -23.04%, Miss. Q1 2026, reported Mar 3, 2026: actual 90.3M USD, estimate 89.53M USD, surprise +0.87%, Beat. Q2 2026, reported May 4, 2026: actual 73.14M USD, estimate 72.52M USD, surprise +0.85%, Beat. Q3 2026, reported Aug 5, 2026: actual 84.08M USD, estimate 81.55M USD, surprise +3.11%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 77.85M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$18.40

119.31% upside
Past 12 months12-month forecastHigh $27.00Average $18.40Low $13.00

Rating distribution

13 ratings
Strong buy00%
Buy1185%
Hold215%
Sell00%
Strong sell00%

Recent analyst actions

6 institutions

EOLS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding EOLS

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
12.65M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
9.02M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
4.66M
Weight
0.03%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
4.51M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
3.32M
Weight
0.59%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
2.57M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
iShares U.S. Pharmaceuticals ETF logoiShares U.S. Pharmaceuticals ETFIHE
Market value
2.03M
Weight
0.12%
AUM
1.74B USD
Expense ratio
0.37%
Price / 1D
$106.79+1.01%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.95M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research EOLS

research.disclaimer